TY - JOUR
T1 - Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)
AU - Nazario, Luiza Reali
AU - Antonioli, Régis
AU - Capiotti, Katiucia Marques
AU - Hallak, Jaime Eduardo Cecílio
AU - Zuardi, Antonio Waldo
AU - Crippa, José Alexandre S
AU - Bonan, Carla Denise
AU - da Silva, Rosane Souza
N1 - Copyright © 2015 Elsevier Inc. All rights reserved.
PY - 2015/8
Y1 - 2015/8
N2 - Cannabidiol (CBD) has been investigated in a wide spectrum of clinical approaches due to its psychopharmacological properties. CBD has low affinity for cannabinoid neuroreceptors and agonistic properties to 5-HT receptors. An interaction between cannabinoid and purinergic receptor systems has been proposed. The purpose of this study is to evaluate CBD properties on memory behavioral and locomotor parameters and the effects of pre-treatment of adenosine receptor blockers on CBD impacts on memory using adult zebrafish. CBD (0.1, 0.5, 5, and 10mg/kg) was tested in the avoidance inhibitory paradigm and anxiety task. We analyzed the effect of a long-term caffeine pre-treatment (~20mg/L - four months). Also, acute block of adenosine receptors was performed in co-administration with CBD exposure in the memory assessment. CBD promoted an inverted U-shaped dose-response curve in the anxiety task; in the memory assessment, CBD in the dose of 5mg/Kg promoted the strongest effects without interfering with social and aggressive behavior. Caffeine treatment was able to prevent CBD (5mg/kg) effects on memory when CBD was given after the training session. CBD effects on memory were partially prevented by co-treatment with a specific A2A adenosine receptor antagonist when given prior to or after the training session, while CBD effects after the training session were fully prevented by adenosine A1 receptor antagonist. These results indicated that zebrafish have responses to CBD anxiolytic properties that are comparable to other animal models, and high doses changed memory retention in a way dependent on adenosine.
AB - Cannabidiol (CBD) has been investigated in a wide spectrum of clinical approaches due to its psychopharmacological properties. CBD has low affinity for cannabinoid neuroreceptors and agonistic properties to 5-HT receptors. An interaction between cannabinoid and purinergic receptor systems has been proposed. The purpose of this study is to evaluate CBD properties on memory behavioral and locomotor parameters and the effects of pre-treatment of adenosine receptor blockers on CBD impacts on memory using adult zebrafish. CBD (0.1, 0.5, 5, and 10mg/kg) was tested in the avoidance inhibitory paradigm and anxiety task. We analyzed the effect of a long-term caffeine pre-treatment (~20mg/L - four months). Also, acute block of adenosine receptors was performed in co-administration with CBD exposure in the memory assessment. CBD promoted an inverted U-shaped dose-response curve in the anxiety task; in the memory assessment, CBD in the dose of 5mg/Kg promoted the strongest effects without interfering with social and aggressive behavior. Caffeine treatment was able to prevent CBD (5mg/kg) effects on memory when CBD was given after the training session. CBD effects on memory were partially prevented by co-treatment with a specific A2A adenosine receptor antagonist when given prior to or after the training session, while CBD effects after the training session were fully prevented by adenosine A1 receptor antagonist. These results indicated that zebrafish have responses to CBD anxiolytic properties that are comparable to other animal models, and high doses changed memory retention in a way dependent on adenosine.
KW - Adenosine A1 Receptor Antagonists/pharmacology
KW - Adenosine A2 Receptor Antagonists/pharmacology
KW - Animals
KW - Avoidance Learning/drug effects
KW - Behavior, Animal/drug effects
KW - Caffeine/pharmacology
KW - Cannabidiol/antagonists & inhibitors
KW - Central Nervous System Stimulants/pharmacology
KW - Dose-Response Relationship, Drug
KW - Memory Disorders/chemically induced
KW - Motor Activity/drug effects
KW - Receptor, Adenosine A2A/drug effects
KW - Zebrafish
U2 - 10.1016/j.pbb.2015.06.008
DO - 10.1016/j.pbb.2015.06.008
M3 - Article
C2 - 26099242
SN - 0091-3057
VL - 135
SP - 210
EP - 216
JO - Pharmacology, Biochemistry and Behavior
JF - Pharmacology, Biochemistry and Behavior
ER -